Floatz logo

Ganetespib

ALL

Synta Pharmaceuticals Corp.Small moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the ALL cohort.

Asset / SponsorPhaseRating
Gm-Csf
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Phase 4BBB
Allogeneic Cd34+-Enriched And Cd45Ra-Depleted Pbscs
Fred Hutchinson Cancer Center
Phase 2/3BBB
ABATACEPT RECOMBINANT
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Phase 3BB
Busulphan
Nantes University Hospital
Phase 2B
Carfilzomib
Amgen
Phase 1CCC

View all 15 →

Same molecule, other indications

Ganetespib is also rated in:

myelodysplastic syndromeDormant
B
Indicative ·
56 / 100
View asset →
lung adenocarcinomaDormant
CCC
Indicative ·
55 / 100
View asset →
ocular melanomaDormant
CCC
Indicative ·
54 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →